TG Therapeutics, Inc.
TGTX
$35.61
-$0.405-1.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 386.39M | 329.00M | 264.79M | 346.73M | 289.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 386.39M | 329.00M | 264.79M | 346.73M | 289.33M |
| Cost of Revenue | 48.59M | 38.49M | 30.94M | 25.11M | 18.72M |
| Gross Profit | 337.80M | 290.52M | 233.85M | 321.62M | 270.62M |
| SG&A Expenses | 170.05M | 154.30M | 146.49M | 137.29M | 129.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 326.57M | 287.08M | 265.30M | 244.88M | 240.98M |
| Operating Income | 59.82M | 41.93M | -505.00K | 101.85M | 48.36M |
| Income Before Tax | 41.74M | 25.59M | -13.89M | 95.78M | 41.62M |
| Income Tax Expenses | 2.59M | 2.21M | 479.00K | 91.00K | 419.00K |
| Earnings from Continuing Operations | 39.15 | 23.38 | -14.36 | 95.69 | 41.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.15M | 23.38M | -14.36M | 95.69M | 41.20M |
| EBIT | 59.82M | 41.93M | -505.00K | 101.85M | 48.36M |
| EBITDA | 59.87M | 42.00M | -408.00K | 102.00M | 48.53M |
| EPS Basic | 0.27 | 0.16 | -0.10 | 0.67 | 0.29 |
| Normalized Basic EPS | 0.18 | 0.11 | -0.06 | 0.42 | 0.18 |
| EPS Diluted | 0.24 | 0.14 | -0.11 | 0.60 | 0.22 |
| Normalized Diluted EPS | 0.16 | 0.10 | -0.06 | 0.38 | 0.14 |
| Average Basic Shares Outstanding | 581.75M | 581.28M | 579.13M | 576.90M | 573.68M |
| Average Diluted Shares Outstanding | 643.15M | 626.59M | 609.44M | 604.60M | 586.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |